#China #Shenzhen #Genomics #MGI Tech #DNBSEQ

MGI Tech Commemorates 10 Years of DNBSEQ™ Technology

MGI Tech Co., Ltd., a key player in innovative life science tools, recently celebrated the tenth anniversary of its proprietary DNBSEQ™ sequencing technology. Launched in 2015, DNBSEQ™ emerged as a catalyst for genomic research, enabling scientists and clinicians worldwide to achieve unprecedented accuracy and cost-efficiency in sequencing. The platform's impressive track record includes over 3,900 installations globally and more than 10,900 peer-reviewed publications that underscore its significance in scientific discovery.

Revolutionizing Genomics with High Performance

The DNBSEQ™ technology utilizes Health's proprietary DNA nanoball (DNB) method and patterned arrays to generate high-quality genomic data. Users have praised this technology for its excellent accuracy, minimal duplication, and efficiency, making it versatile enough for whole-genome sequencing (WGS), whole-exome sequencing (WES), and various other applications.

Over the past decade, DNBSEQ™ has redefined the landscape of genomic technology, providing unprecedented throughput and coverage. Today, the product line includes the ultra-high-throughput DNBSEQ-T20×2, which helped deliver the world’s first human genome under $100. The popular DNBSEQ-T7 provides high-throughput versatility, while the compact DNBSEQ-E25 is tailored for fieldwork and decentralized testing. MGI’s flagship model, the DNBSEQ-T1+, exemplifies the company's commitment to continuous innovation, offering researchers a powerful, fast, and flexible benchtop solution.

Broadening Applications Across Scientific Fields

DNBSEQ™ technology transcends mere sequencing capabilities; it opens avenues for various multi-omics applications, including genomics, transcriptomics, epigenomics, and spatial omics. This versatility is crucial for understanding complex biological systems, disease mechanisms, and interactions with the environment, allowing researchers to gain deeper insights into both health and ecological issues.

The technology’s resilience has also been tested in extreme conditions, from the depths of the Mariana Trench to the towering heights of Mount Everest, consistently delivering dependable and high-quality results. This reliability is paramount as scientists seek to explore and elucidate the complexities of life.

Streamlining Scientific Endeavors

To enhance research workflows, MGI offers end-to-end solutions that simplify the entire process—from sample preparation to data analysis. These automation and BIT tools significantly improve efficiency by minimizing manual efforts, thus expanding access to advanced genomic tools for researchers in labs of any size.

MGI's motto, “What if science had no barriers?” drives its mission to eliminate bottlenecks and reduce costs, enabling scientists to focus on discovery rather than operational complexity.

Aiming for the $10 Genome

As MGI looks into the future, the company's vision culminates in the ambitious target of achieving the $10 genome. Continuously building on the DNBSEQ™ foundation, MGI is dedicated to developing next-generation sequencing technologies to further improve accessibility, reduce costs, and expedite research outcomes.

Dr. Rade Drmanac, Chief Scientific Officer of MGI, emphasized the journey of DNBSEQ™ from an innovative concept to a global benchmark in the field of high-quality, affordable sequencing. “We’ve opened doors for researchers everywhere, and now we’re building the next chapter in accessible genomics,” he remarked, reflecting on the decade of substantial progress.

Commitment to Accessible Genomics

The tenth anniversary celebration is not just a milestone—it also reaffirms MGI's overarching mission of making genomics broadly accessible, affordable, and impactful for all. By equipping researchers with robust tools to drive discovery, MGI aims to contribute to a healthier, more informed, and interconnected world, one genome at a time.

For those interested in learning more about DNBSEQ™ technology and MGI’s comprehensive product offerings, further information can be found online.

About MGI

Founded in 2016, MGI Tech Co., Ltd. is at the forefront of life science innovation, emphasizing research, development, and the manufacturing of state-of-the-art genomic instruments. With a global presence and commitment to advancing health, agriculture, and biotechnology, MGI is dedicated to revolutionizing life sciences for the benefit of a more inclusive future.